The renewal of psychedelic research: Implications for humanistic and transpersonal psychology

Humanistic Psychologist

Volumn 34, Issue 1, 2006, Pages

  Friedman, Harris ^a  

^a SAYBROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85071204732     PISSN: 08873267     EISSN: 15473333     Source Type: Journal    
DOI: 10.1207/s15473333thp3401_5     Document Type: Article

References (79)

1. Aaronson, B., & Osmond, H. (1970). Introduction. In B. Aaronson & H. Osmond (Eds.), Psychedelics (pp. 3–18). Garden City, NY: Doubleday.
2. Aghajanain, G., & Marek, G. (2000). Serotonin model of schizophrenia: Emerging role of glutamate mechanisms. Brain Research Reviews, 31, 302–312.
3. Albee, G. (2002). Just say no to psychotropic drugs! Journal of Clinical Psychology, 58, 635–649.
4. Barlow, D. (2004). Psychological treatments. American Psychologist, 59, 869–878.
5. Baruss, I. (2003). Alterations of consciousness: An empirical analysis for social scientists. Washington, DC: American Psychological Association.
6. Benedict, R. (1934). Patterns of culture. New York: Houghton Mifflin.
7. Blewett, D., & Chwelos, N. (1959). A handbook for the therapeutic use of LSD-25. Retrieved December 7, 2004, from http://www.maps.org/ritesofpassage/new/hb.html
8. Bravo, G., & Grob, C. (1996). Psychedelic psychotherapy. In B. Scotton & A. Chinen (Eds.), Textbook of transpersonal psychiatry and psychology (pp. 335–343). New York: Basic Books.
9. Caldwell, W. (1979). LSD psychotherapy: An exploration of psychedelic and psycholytic therapy. Berkeley, CA: Grove Press.
10. Check, E. (2004). The ups and downs of ecstasy. Nature, 429, 126–128.
11. Clark, W., Lieff, J., & Sussman, R. (1975). Psychedelic research: Obstacles and values. Journal of Humanistic Psychology, 15, 5–17.
12. Cornwell, B., & Linders, A. (2002). The myth of “moral panic”: An alternative account of LSD prohibition. Deviant Behavior, 23, 307–330.
13. de Jonghe, F., Hendrikson, M., van Aalst, G., Gerda, S., Kool, J., Peen, R., et al. (2004). Psychotherapy alone and combined with pharmacotherapy in the treatment of depression. British Journal of Psychiatry, 185, 37–45.
14. Dishotsky, N., Loughman, W., Mogar, R., & Lipscomb, W. (1971). LSD and genetic damage. Science, 172, 431–440.
15. Dobkin de Rios, M. (1990). Hallucinogens: Cross-cultural perspectives. Bridport, UK: Prism.
16. Dobkin de Rios, M., & Janiger, O. (2003). LSD, spirituality, and the creative process. Rochester, VT: Park Street.
17. Doblin, R. (2002). A clinical plan for MDMA (ecstasy) in the treatment of posttraumatic stress disorder (PTSD): Partnering with the FDA. Journal of Psychoactive Drugs, 34, 185–194.
18. Doblin, R., Halpern, J., Mithoefer, M., Grob, C., Mojeiko, V., Stamer, J., et al. (2004). The psychedelic research panel: A vision for the 21st century. Retrieved December 20, 2004, from http://maps.org/avarchive/ita16/index.html.
19. Eisner, B. (2002). Remembrances of LSD therapy past. Retrieved December 7, 2004, from http://www.maps.org/books/remembrances.html
20. Ferrer, J. (2002). Revisioning transpersonal theory: A participatory vision of human spirituality. Albany, NY: State University of New York Press.
21. Forte, R. (Ed.) (2000). Entheogens and the future of religion. Thousand Oaks, CA: Pine Forge Press.
22. Friedman, H. (1983). The Self-Expansiveness Level Form: A conceptualization and measurement of a transpersonal construct. Journal of Transpersonal Psychology, 15, 37–50.
23. Friedman, H. (2002). Prescription privileges: A Pyrrhic victory? Florida Psychologist, 53, 10–11.
24. Friedman, H. (2004a). Mad pride about prescription privileges. The National Psychologist, 13(6), 13–21.
25. Friedman, H. (2004b). The remarkable resurgence of psychedelic research. Florida Psychologist, 55, 14–15.
26. Friedman, H. (2005). Problems of romanticism in transpersonal psychology: A case study of Aikido. The Humanistic Psychologist, 33, 3–24.
27. Friedman, H., & MacDonald, D. (2002). Using transpersonal tests in humanistic psychological assessment. The Humanistic Psychologist, 30, 223–236.
28. Friedman, H., MacDonald, D., & Kumar, K. (2004, March). Cross-cultural validation of the Self-Expansiveness Level Form with an Indian sample. Journal of Indian Psychology, 44–56.
29. Gable, S. (1993). Toward a comparative overview of dependence potential and acute toxicity of psychoactive substances used nonmedically. American Journal of Drug & Alcohol Abuse, 19, 263–281.
30. Gatchel, R. (2004). Comorbidity of chronic pain and mental health disorders: The biopsychosocial perspective. American Psychologist, 59, 795–805.
31. Green, R., Cross, A., & Goodwin, G. (1995). Review of the pharmacology and clinical pharmacology of 2,3-methylenedioxymethamine (MDMA or Ecstasy). Psychopharmacology, 119, 247–260.
32. Grinspoon, L. (1986). Can drugs be used to enhance the psychotherapeutic process? American Journal of Psychotherapy, 40, 393–404.
33. Grinspoon, L. & Bakalar, J. (Eds.). (1979). Psychedelic drugs reconsidered. New York: Viking.
34. Grof, S. (1980). LSD Psychotherapy. Pomona, California: Hunter House.
35. Grof, S. (n.d.). Untitled. Retrieved October 10, 2004, from http://www.maps.org/cgi-bin/thatsanorder_LE
36. Halpern, J, (1996). The use of hallucinogens in the treatment of addiction. Addiction Research, 4, 177–189.
37. Halpern, J. (2004a). MDMA for cancer-related anxiety and LSD/psilocybin for cluster headaches. Multidisciplinary Association for Psychedelic Studies, XIV, 6.
38. Halpern, J. (2004b). MDMA-assisted psychotherapy in advanced-stage cancer patients with anxiety. Retrieved October 10, 2004, from www.maps.org/research/mdma/mdmacanceranxietyprotocol.pdf.
39. Jenks, S. (1995). An analysis of risk reduction among organized groups that promote marijuana and psychedelic drugs. Journal of Drug Issues, 25, 629–647.
40. Krupitsky, E., & Grinenko, A. (1997). Ketamine psychedelic therapy (KPT): A review of the results of ten years of research. Journal of Psychoactive Drugs, 29, 165–183.
41. Kurtzweil, P. (1995, September). Medical possibilities for psychedelic drugs. U.S. Food and Drug Administration Consumer Magazine, n.p. Retrieved December 23, 2004, from http://www.fda.gov/fdac/features/795_psyche.html.
42. Ludwig, A., Levine, J., & Stark, L. (1970). LSD and alcoholism: A clinical study of treatment efficacy. Springfield, IL: Charles C. Thomas.
43. Lukoff, D., Lu, F., & Turner, R. (1998). From spiritual emergency to spiritual problem: The transpersonal roots of the new DSM-IV category. Journal of Humanistic Psychology, 38(2), 21–50.
44. MacDonald, D., Gagnier, J., & Friedman, H. (2000). The Self-Expansiveness Level Form: Examination of its validity and relation to the NEO Personality Inventory-Revised. Psychological Reports, 86, 707–726.
45. Mack, J. (1993). Nonordinary states of consciousness and the accessing of feelings. In S. Ablon & D. Brown (Eds.), Human feelings: Explorations in affect development and meaning (pp. 357–371). Hillsdale, NJ: The Analytic Press.
46. Martin, D. (2004, February 22). Humphrey Osmond, 86, who sought medicinal value in psychedelic drugs, dies. New York Times, 25.
47. McGlothlin, W. (1985). A chemistry for world peace. Journal of Drug Issues, 15, 225–245.
48. Mears, F. (2004). A brief history and current use of psychostimulants. The National Psychologist, 13(6), 6.
49. Merkur, D. (2001). The psychedelic sacrament: Manna, meditation, and mystical experience. Rochester, VT: Park Street Press.
50. Mithoefer, M. (2004). MDMA-assisted psychotherapy in the treatment of posttraumatic stress disorder. Multidisciplinary Association for Psychedelic Studies, XIV, 3–4.
51. Mojeko, V. (2004). Developing an outcome study of ibogaine therapy. Multidisciplinary Association for Psychedelic Studies, XIV, 7–8.
52. Morgan, M. (2000). Ecstasy (MDMA): A review of its possible persistent psychological effects. Psychopharmacology, 152, 230–248.
53. Multidisciplinary Association for Psychedelic Studies. (n.d.). Research studies. Retrieved December 20, 2004, from http://www.maps.org/research
54. Newnes, C. (2004). Psychology and psychotherapy’s potential for countering the medicalization of everything. The Humanistic Psychologist, 44, 358–376.
55. Nichols, D. (1986). Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens: Identification of a new therapeutic class: Entactogens. Journal of Psychoactive Drugs, 18, 305–313.
56. Passie, Y. (1997). Psycholytic and psychedelic research 1931–1995: A complete international bibliography. Hannover, Germany: Laurentius.
57. Pletscher, A. & Ladewig, D. (Eds.). (1994). 50 years of LSD. Current status and perspectives of hallucinogens. New York: Parthenon.
58. Riba, J., Rodríguez-Fornells, A., & Barbanoj, M. (2002). Effects of ayahuasca on sensory and sensorimotor gating in humans as measured by P50 suppression and prepulse inhibition of the startle reflex, respectively. Psychopharmacology, 1, 18–29.
59. Ricaurte, G., Yuan, J., Hatzidimitrou, G., Cord, B., & McCann, U. (2002). The perils of ecstasy. Science, 297, 2260–2263.
60. Ricaurte, G., Yuan, J., Hatzidimitrou, G., Cord, B., & McCann, U. (2003). Retraction. Science, 301, 1479.
61. Richards, W., Rhead, J., DiLeo, F., Yensen, R., & Kurland, A. (1977). The peak experience variable in DPT-assisted psychotherapy with cancer patients. Journal of Psychedelic Drugs, 9, 1–10.
62. Roberts, T., & Hruby, P. (2002). Toward an entheogen research agenda. Journal of Humanistic Psychology, 42, 71–89.
63. Rossi, E. (2004). Stress-induced alternative gene splicing in mind-body medicine. Advances in Mind-Body Medicine, 20, 12–19.
64. Russell, D. (1998). Shamanism and the drug propaganda: The birth of patriarchy and the drug war. Camden, NY: Kalyx.
65. Sauna, V. (1995). “Prescription privileges” vs. psychologists’ authority: Psychologists do better without drugs. The Humanistic Psychologist, 23, 187–212.
66. Smith, A., & Tart, C. (1998). Cosmic consciousness experience and psychedelic experiences: A first person comparison. Journal of Consciousness Studies, 5, 97–107.
67. Smith, H. (2003). Cleansing the doors of perception: The religious significance of entheogenic plants and chemicals. Boulder, CO: Sentient Publications.
68. Smith, H., Grob, C., Jesse, R., Bravo, G., Agar, A., & Walsh, R. (2004). Do drugs have religious import? A 40-year retrospective. Journal of Humanistic Psychology, 4, 120–140.
69. Spartos, C. (2004, March 10). The ecstasy factor: Bad science slandered a generation’s favorite drug…. Village Voice. Retrieved June 23, 2004, from http://www.maps.org/media/vv031004.html
70. Stolaroff, M. (1997). The secret chief: Conversations with a pioneer of the underground psychedelic therapy movement. Sarasota, FL: Multidisciplinary Association for Psychedelic Studies.
71. Stolaroff, M. (1999). Are psychedelics useful in the practice of Buddhism? Journal of Humanistic Psychology, 39, 60–80.
72. Strassman, R. (1984). Adverse reactions to psychedelic drugs: A review of the literature. Journal of Nervous & Mental Disease, 172, 577–595.
73. Strassman, R. (2001). Where to with psychedelic research? Retrieved December 20, 2004, from http://leda.lycaeum.org/?ID=16881
74. Tart, C. (1972). States of consciousness and state-specific sciences. Science, 176, 1203–1210.
75. Victor, B. (1999). Transpersonal psychiatry and psychopharmacologic practice. Psychiatric Annals, 29, 465–468.
76. Walsh, R. (1993). The transpersonal movement: A history and state of the art. Journal of Transpersonal Psychology, 25, 123–139.
77. Walsh, R. (2003). Entheogens: True or false. International Journal of Transpersonal Studies, 22, 1–5.
78. Wilber, K. (1979). Eye to eye: Transpersonal psychology and science. ReVision, 2, 3–25.
79. Williams, L. (1999). Human psychedelic research: A historical and sociological analysis. Unpublished thesis, Cambridge University. Retrieved November 20, 2004, from http://www.maps.org/docs/psy-che.html#_ftn2